Compliance With ERAS Protocol in Pancreatic Surgery, Stress Response and Outcomes

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity of Thessaly

About this trial

The purpose of this study is to evaluate the impact of compliance with enhanced recovery after surgery (ERAS) program on patient reported outcomes (PROs), surgery-specific outcomes and stress response after pancreatic surgery.

This prospective observational study will include all consecutive patients undergoing pancreatic surgery over a period of three years (2022 - 2025) at two sites, namely University General Hospital of Larissa and IASO Thessalias, in Greece. Patients will be prospectively enrolled after written informed consent. Data will be collected on patient characteristics, surgical and anaesthetic techniques, complications, and length of stay. Quality of life questionnaires will be administered to patients preoperatively, on the fith postoperative day, first follow-up after discharge, one month and six months after the operation. The stress response will be assessed by measuring the Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio (NLR and PLR) preoperatively, and on the first five postoperative days. Data will be collected on pancreatic surgery-specific complications such as delayed gastric emptying (DGE), post-pancreatectomy haemorrhage (PPH) and postoperative pancreatic fistula (POPF) formation. Anonymised data will be uploaded by the principal investigator on a protected excel spreadsheet for analysis.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

all pancreatic surgery patients

above the age of 18

fluent greek speakers

without communication barriers

Disqualifiers

younger than 18 years-old

unable or unwilling to participate

other surgical procedures

communication barriers

Trial population

All consecutive community patients presented for pancreatic surgery

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • ERAS protocol

    Procedure/Surgery

    ERAS protocol as described above

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Change in patient-reported outcomes as measured by the Health Questionnaire EORTC QLQ-C30

This questionnaire assesses health related quality of life (HRQoL) for cancer patients and includes 30 questions. The QLQ-C30 includes five functional scales (physical, role, emotional, cognitive, and social functioning); eight symptom scales or single items (fatigue, pain, nausea/vomiting, dyspnea, insomnia, appetite loss, constipation, and diarrhea); an item to assess financial difficulties; 1 global health status scale; and 1 global quality of life scale. Each one of the first 28 items has 4 levels: 1 = not at all, 2 = a little, 3 = quite a bit, 4 = very much. The last 2 questions ask the patient to rate their own health and quality of life on a scale from 1 (very poor) to 7 (excellent). PROMs questionnaires will be distributed in paper format and filled out by pen.

Time frame
1 week to 1 day before the operation, postoperative day 5, first follow-up 1 week post discharge, 1 month, and 6 months after the operation
2

Change on the stress response to surgery measured by the Neutrophil-Lymphocyte and Platelet-Lymphocyte Ratio (NLR and PLR).

NLR and PLR will be calculated by blood tests

Time frame
1 week to 1 day before the operation, and postoperative days 1-5
3

Rate of Delayed Gastric Emptying (DGE)

Number of DGE defined and graded according to the International Study Group of Pancreatic Surgery (ISGPS).

Time frame
within 6 weeks from operation
4

Rate of Post Pancreatic Fistula (POPF) formation

Number of POPF defined and graded according to the International Study Group of Pancreatic Fistula (ISGPF).

Time frame
within 6 weeks from operation

Secondary outcomes

1

Length of hospital stay (LOS)

Total number of days spent in the hospital (including any readmission)

Time frame
within 6 weeks from operation
2

Overall morbidity rate

Number of any perioperative adverse events graded according to Clavien-Dindo

Time frame
Within 3 months from operation
3

Cancer recurrence rate

Number of patients with cancer recurrence with metastases

Time frame
within 1 year from operation

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Thessaly

Lead sponsor

IASO Thessalias

Collaborator

Larissa University Hospital

Collaborator